◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

NGL Fine-Chem Limited (NGLFINE) Financial History

Name: NGL Fine-Chem Limited (NGLFINE) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

NGL Fine-Chem Limited (NGLFINE) operates in the Drug Manufacturers - General industry and is headquartered in Mumbai, India with about 498 employees. Its market capitalization is roughly ₹17 billion. In the fiscal year ended 2026-03-31, NGLFINE reported ₹4.9B in revenue and ₹481M in net income.

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally.

Interactive charts & full statements →

NGLFINE Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹4.9B	₹3.6B	₹3.3B	₹2.7B
Gross Profit	₹2.5B	₹1.8B	₹1.8B	₹1.3B
Operating Income (EBIT)	₹607M	₹226M	₹421M	₹237M
Net Income	₹481M	₹211M	₹413M	₹205M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGLFINE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹1.4B	₹1.5B	₹1.3B	₹1.2B	₹1.0B
Gross Profit	₹778M	₹783M	₹680M	₹630M	₹523M
Operating Income (EBIT)	₹180M	₹164M	₹171M	₹121M	₹67M
Net Income	₹184M	₹135M	₹157M	₹96M	₹92M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGLFINE Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹11M)	(₹11M)	(₹11M)	(₹11M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGLFINE Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹5.5B	₹4.3B	₹3.6B	₹2.9B	—
Total Liabilities	₹2.2B	₹1.5B	₹929M	₹645M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NGLFINE viewer.

Other Companies in Drug Manufacturers - General

4552 · JCR Pharmaceuticals Co., Ltd. — JPY 63 billion
BAYN · Bayer Aktiengesellschaft — €47 billion
SMSPHARMA · SMS Pharmaceuticals Limited — ₹41 billion
SAIPARENT · Sai Parenteral's Limited — ₹23 billion
TTKHLTCARE · TTK Healthcare Limited — ₹15 billion
2630 · Vigonvita Life Sciences Co., Ltd. — HK$14 billion
KOPRAN · Kopran Limited — ₹13 billion
9637 · Alebund Pharmaceuticals (Jiangsu) Limited — HK$8 billion

← NGIL All “N” companies NGNE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.